IBDEI39S ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,54951,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,54951,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,54951,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,54952,0)
 ;;=C82.40^^256^2775^71
 ;;^UTILITY(U,$J,358.3,54952,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54952,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,54952,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,54952,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,54953,0)
 ;;=C82.99^^256^2775^72
 ;;^UTILITY(U,$J,358.3,54953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54953,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,54953,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,54953,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,54954,0)
 ;;=C82.90^^256^2775^73
 ;;^UTILITY(U,$J,358.3,54954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54954,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,54954,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,54954,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,54955,0)
 ;;=R59.1^^256^2775^58
 ;;^UTILITY(U,$J,358.3,54955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54955,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,54955,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,54955,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,54956,0)
 ;;=C91.40^^256^2775^77
 ;;^UTILITY(U,$J,358.3,54956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54956,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,54956,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,54956,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,54957,0)
 ;;=C91.42^^256^2775^75
 ;;^UTILITY(U,$J,358.3,54957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54957,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,54957,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,54957,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,54958,0)
 ;;=C91.41^^256^2775^76
 ;;^UTILITY(U,$J,358.3,54958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54958,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,54958,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,54958,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,54959,0)
 ;;=D57.01^^256^2775^78
 ;;^UTILITY(U,$J,358.3,54959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54959,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,54959,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,54959,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,54960,0)
 ;;=D57.00^^256^2775^79
 ;;^UTILITY(U,$J,358.3,54960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54960,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,54960,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,54960,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,54961,0)
 ;;=D57.02^^256^2775^80
 ;;^UTILITY(U,$J,358.3,54961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54961,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,54961,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,54961,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,54962,0)
 ;;=D68.32^^256^2775^82
 ;;^UTILITY(U,$J,358.3,54962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54962,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,54962,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,54962,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,54963,0)
 ;;=C22.2^^256^2775^83
 ;;^UTILITY(U,$J,358.3,54963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54963,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,54963,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,54963,2)
 ;;=^5000935
